-
公开(公告)号：US20070155703A1
公开(公告)日：2007-07-05
申请号：US11706925
申请日：2007-02-15
申请人： Jin-An Jiao , Lawrence Luepschen , Esperanza Nieves , Hing Wong , Dean Taylor
发明人： Jin-An Jiao , Lawrence Luepschen , Esperanza Nieves , Hing Wong , Dean Taylor
IPC分类号： A61K31/675 , A61K31/66
CPC分类号： C07F9/3873 , A61K31/66 , A61K31/663 , A61K31/675 , C07F9/386
摘要： The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.
摘要翻译： 本发明包括药物活性化合物和治疗方法以及利用或包含一种或多种这类化合物的药物组合物。 本发明的化合物特别可用于治疗或预防不期望的血栓形成。
-
2.发明申请公开(公告)号：US20050271664A1
公开(公告)日：2005-12-08
申请号：US11087528
申请日：2005-03-22
申请人： Hing Wong , Jin-An Jiao , Esperanza Nieves , Lawrence Luepschen
发明人： Hing Wong , Jin-An Jiao , Esperanza Nieves , Lawrence Luepschen
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P7/02 , A61P9/00 , C07K16/28 , C07K16/36 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/08 , C12Q1/68 , C07K16/22
CPC分类号： C07K16/36 , A61K38/00 , A61K39/395 , A61K2300/00
摘要： The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
摘要翻译： 本发明包括通过以高亲和力和特异性结合天然人TF而提供优异的抗凝血活性的抗体。 本发明的抗体可有效抑制体内血液凝固。 本发明的抗体可以单独或存在于TF：VIIa复合物中的天然人TF结合，有效地防止因子X结合TF或该复合物，从而减少血液凝固。 本发明优选的抗体特异性结合主要为天然人TF的构象表位，该表位提供意想不到的强抗体结合位点。
-
公开(公告)号：US20060039901A1
公开(公告)日：2006-02-23
申请号：US11122622
申请日：2005-05-05
申请人： Jin-An Jiao , Hing Wong , Esperanza Nieves , Lawrence Luepschen
发明人： Jin-An Jiao , Hing Wong , Esperanza Nieves , Lawrence Luepschen
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/36 , A61K2039/505 , C07K16/467 , C07K2317/24 , C07K2319/00
摘要： The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.
-
公开(公告)号：US20060235209A9
公开(公告)日：2006-10-19
申请号：US10310113
申请日：2002-12-04
申请人： Jin-An Jiao , Hing Wong , Esperanza Nieves , Luis Mosquera
发明人： Jin-An Jiao , Hing Wong , Esperanza Nieves , Luis Mosquera
IPC分类号： A61K39/395 , C07K16/42
CPC分类号： C07K16/36 , A61K2039/505 , C07K16/467 , C07K2317/24 , C07K2319/00
摘要： Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.
-
公开(公告)号：US07199113B2
公开(公告)日：2007-04-03
申请号：US11005871
申请日：2004-12-06
IPC分类号： A01N57/00 , A61K31/675
CPC分类号： C07F9/3873 , A61K31/66 , A61K31/663 , A61K31/675 , C07F9/386
摘要： The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.
-
公开(公告)号：US06828312B2
公开(公告)日：2004-12-07
申请号：US09406269
申请日：1999-09-24
IPC分类号： A61K3166
CPC分类号： C07F9/3873 , A61K31/66 , A61K31/663 , A61K31/675 , C07F9/386
摘要： The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.
摘要翻译： 本发明包括药物活性化合物和治疗方法以及利用或包含一种或多种这类化合物的药物组合物。 本发明的化合物特别可用于治疗或预防不期望的血栓形成。
-
公开(公告)号：US07824677B2
公开(公告)日：2010-11-02
申请号：US12136718
申请日：2008-06-10
IPC分类号： A61K39/395
CPC分类号： C07K16/36 , A61K38/00 , A61K39/395 , A61K2300/00
摘要： The invention includes methods of inhibiting blood coagulation using antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Methods of the invention can effectively inhibit blood coagulation in vivo. Antibodies used in the methods of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies used in the methods of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
摘要翻译： 本发明包括使用通过以高亲和性和特异性结合天然人TF提供优异抗凝血活性的抗体来抑制血液凝固的方法。 本发明的方法可有效抑制体内血液凝固。 用于本发明方法的抗体可以单独或存在于TF：VIIa复合物中的天然人TF结合，有效地防止因子X结合TF或该复合物，从而减少血液凝固。 用于本发明方法的优选抗体特异性结合构成天然人TF的构象表位，该表位提供了意想不到的强抗体结合位点。
-
公开(公告)号：US20090041766A1
公开(公告)日：2009-02-12
申请号：US12136718
申请日：2008-06-10
IPC分类号： A61K39/395
CPC分类号： C07K16/36 , A61K38/00 , A61K39/395 , A61K2300/00
摘要： The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
-
公开(公告)号：US5986065A
公开(公告)日：1999-11-16
申请号：US814806
申请日：1997-03-10
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P7/02 , A61P9/00 , C07K16/28 , C07K16/36 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/08 , C12Q1/68
CPC分类号： C07K16/36 , A61K39/395 , A61K38/00
摘要： The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
-
10.发明授权公开(公告)号：US06555319B2
公开(公告)日：2003-04-29
申请号：US09293854
申请日：1999-04-16
IPC分类号： G01N3353
CPC分类号： C07K16/36 , A61K38/00 , A61K39/395 , A61K2300/00
摘要： The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.
摘要翻译： 本发明包括通过以高亲和力和特异性结合天然人TF而提供优异抗凝血活性的抗体。 本发明的抗体可有效抑制体内血液凝固。 本发明的抗体可以单独或存在于TF：VIIa复合物中的天然人TF结合，有效地防止因子X结合TF或该复合物，从而减少血液凝固。 本发明优选的抗体特异性结合主要为天然人TF的构象表位，该表位提供意想不到的强抗体结合位点。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.031 秒)
